Levi & Korsinsky is investigating whether Altria Group misdescribed the FDA regulatory status of its on! PLUS nicotine pouch product and the likelihood of near-term FDA authorizations for additional applications....
MO Q2 Deep Dive: Margin Pressure Amid Consumer Strain and Smoke-Free Investments
Altria (NYSE:MO) Posts Better-Than-Expected Sales In Q2 CY2026
Altria Group, Inc. (NYSE: MO) today reports our 2026 second-quarter and first-half business results and narrows guidance for 2026 full-year adjusted diluted earnings per share (EPS). “In the...
September S&P 500 E-Mini futures (ESU26) are up +0.48%, and September Nasdaq 100 E-Mini futures (NQU26) are up +1.02% this morning as investors cheered strong growth in Microsoft’s cloud business, signaling...
Barchart Research What to Expect from MO Earnings MO Generated July 29, 2026 Current Price $74.92 EPS Estimate $$1.50 Consensus Rating Hold Average Move 4.66% Altria's Pricing Strategy Faces Its First...
Earnings To Watch: Altria (MO) Reports Q2 Results Tomorrow
Philip Morris International ($PM) said it has doubled its planned investment in its Aurora, Colorado manufacturing campus to approximately $1.2 billion through 2028, expanding production of ZYN nicotine...
Altria's Dividend King reputation faces another important test in the upcoming Q2 earnings report as investors look beyond its shrinking cigarette business.